Financial Statements

CRISPR Therapeutics AG (CRSP)

$54.76

+0.40 (+0.74%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018 2017
Retained Earnings (Previous Year) -574-225-292-125-
Net Income 378-34967-165-68
Stock Dividends ----1-57
Dividend Paid -----
Retained Earnings -196-574-225-292-125

PPE Schedule

Year 2021 2020 2019 2018 2017
Gross PPE 93731919-
Annual Depreciation 3013961227
Capital Expenditure -82-18-7-3-8
Net PPE 31293731919

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018 2017
Intangible and Goodwill (Previous Year) -----
New Purchases -1---594-1,509
Intangible and Goodwill -----

CRISPR Therapeutics AG income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes CRISPR Therapeutics AG FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.